OROS® oxybutynin or Ditropan® — Competitive Intelligence Brief

OROS® oxybutynin or Ditropan® (OROS® oxybutynin or Ditropan®) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anticholinergic agent. Area: Urology / Neurology.

phase 3 Anticholinergic agent Muscarinic acetylcholine receptor (M3) Urology / Neurology Small molecule

Target snapshot

OROS® oxybutynin or Ditropan® (OROS® oxybutynin or Ditropan®) — Alza Corporation, DE, USA. Oxybutynin is an anticholinergic agent that blocks muscarinic acetylcholine receptors in the bladder smooth muscle, reducing involuntary contractions and increasing bladder capacity.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
OROS® oxybutynin or Ditropan® TARGET	OROS® oxybutynin or Ditropan®	Alza Corporation, DE, USA	phase 3	Anticholinergic agent	Muscarinic acetylcholine receptor (M3)
Ecclock	SOFPIRONIUM BROMIDE	Kaken Pharmaceutical	marketed		Muscarinic acetylcholine receptor M3	2024-01-01
Yupelri	REVEFENACIN	Mylan Ireland Ltd	marketed	Anticholinergic [EPC]	Muscarinic acetylcholine receptor M3	2018-01-01
Spiriva	TIOTROPIUM BROMIDE	Boehringer Ingelheim	marketed	Anticholinergic	Muscarinic acetylcholine receptor M3	2004-01-01
Enablex	DARIFENACIN	AbbVie	marketed	Cholinergic Muscarinic Antagonist	Muscarinic acetylcholine receptor M3	2004-01-01
Sanctura	TROSPIUM	AbbVie	marketed	Cholinergic Muscarinic Antagonist	Muscarinic acetylcholine receptor M3	2004-01-01
Librax	CLIDINIUM	Roche	marketed	Anticholinergic	Muscarinic acetylcholine receptor M3	1982-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anticholinergic agent class)

1. Repurposed Therapeutics, Inc. · 2 drugs in this class
2. University of Iowa · 2 drugs in this class
3. Alza Corporation, DE, USA · 2 drugs in this class
4. Janssen-Cilag Ltd.,Thailand · 1 drug in this class
5. Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · 1 drug in this class
6. Rutgers, The State University of New Jersey · 1 drug in this class
7. Stony Brook University · 1 drug in this class
8. Toronto Rehabilitation Institute · 1 drug in this class
9. US Department of Veterans Affairs · 1 drug in this class
10. University of California, Davis · 1 drug in this class